Ozempic Lawsuit Update, News (April 3, 2026) Litigation History

Ozempic lawsuit update: April 3rd, 2026:

We have compiled this ozempic lawsuit update, so that victims and their legal counsel can stay apprised of news, developments and updates concerning the GLP-1 weight loss lawsuits pending in federal and state courts. This post provides an extensive history with detailed updates concerning- Ozempic lawsuit latest news. This specifically includes the history of Mounjaro, Wegovy, Zepbound and other GLP-1 lawsuit. In addition, this update and timeline provides information concerning the latest news about GLP-1 medications and the marketing and regulation of these weight loss drugs.

April 3,2026-

The US Food and Drug Administration issued a formal approval of a second weight loss GLP-1 medication pill, Foundayo.  The orforglipron pill, named Foundayo, is manufactured by Eli Lilly. Foundayo will enter the marketplace only months after the FDA greenlighted the pill version of Novo Nordisk’s injectable weight loss medication, Wegovy. Both pills offer a new way to take GLP-1 medicines. According to  Lilly marketing,  Foundayo constitutes an advancement for GLP-1s in general because, unlike the Wegovy pill, the Foundayo pill can be popped at all hours of the day and there are no restrictions on food and water.

April 2, 2026-

Farmers in the United Kingdom complain that they have no choice but to discard thousands of tons of potatoes they stored because sales are declining. Andy Goodacre, an owner of a farm in the UK states that demand from supermarkets decreased in last couple of years as a result of the increased prominence and usage of GLP-1 medications.

April 1, 2026-

Novo Nordisk has again slashed the prices of Ozempic and Wegovy by up to 35% and 47% in India. Novo’s goal is to compete against less expensive generic medications made by Indian drugmakers. India’s Ozempic and Wegovy marketplace is in turmoil because the the Danish corporation’s patent on Semaglutide expired on March 20, 2026.

March 28, 2026 -Novo to cut Ozempic & Wegovy list prices nearly 50% beginning in 2027

Novo Nordisk stated that it will slash list prices for its popular weight loss drugs Wegovy and Ozempic to $675 per month starting Jan. 1, 2027. The sales tactic, which occurred at a period of time when competition intensified from the likes of Eli Lilly, constitutes a nearly 50% price slash for Wegovy and a nearly 35% price cut for Ozempic meds. The reduced list prices will mostly inure to the benefit of insured persons whose co-payment expenses are tied to a medication’s sticker price. This specifically includes patients with high deductibles or even those people with coinsurance. Novo announced the price alteration will not involve pre-existing discount programs for patients who pay cash.

March 20, 2026- Elderly woman’s death sparks Ozempic lawsuit

An Ozempic law firm has filed a wrongful death lawsuit against Novo Nordisk alleging that a 76-year-old woman who had an Ozempic prescription died as a result of stomach paralysis. Marsha Ettinghoff’s family asserts that she was prescribed Ozempic for about six months when she fell ill and died.

March 16, 2026- MDL Judge orders a “Science day” for attorneys to educate Judge about GLP-1s

The U.S. District Judge presiding over the GLP-1 MDL (3163) vision loss litigation has demanded that lawyers make educational presentations this summer to assist the jurist to better comprehend the science underlying the GLP-1 drugs and their asserted associations to lasting vision damage and blindness. The Judge may be interested in a July 2024 Harvard study linking GLP-1 use to non-arteritic anterior ischemic optic neuropathy (NAION). Harvard scientists determined that Ozempic and Wegovy prescription holders had a seven times greater likelihood of NAION as compared to patients prescribed medications not containing semaglutide. Semaglutide is the active ingredient in both Wegovy and Ozempic. Judge Marston required the GLP-1 lawyers to help educate the court on the science of the case. The “Science Day” is scheduled for June 2, 2026.  Both sides will be given an opportunity to present non-adversarial information to the court.

In case management order #6, court order (PDF), issued by Judge Marston on March 16, the Jurist set forth how the Science Day will move forward. Each side, Plaintiffs and Defendants will be allowed 2.5 hours to set forth their respective presentation. The order states: “Neither the transcript nor any demonstrative aids shall be discoverable, admissible, or used in any fashion for impeachment purposes or for collateral attack. To the extent the parties share materials used by their side on Science Day, the receiving parties shall not share those beyond the litigation.

March 9, 2026- Hims and Novo settle litigation and Hims will NOW sell Novo’s medication

Hims & Hers and Novo Nordisk have reached a peace deal and settled acrimonious litigation between the two healtchcare giants. The deal allows both companies to profit from the settlement, a classic win-win situation. After a longstanding and sometimes bitter feud playing out in a courtroom, the two entities reached a deal that will permit Novo’s drugs Ozempic and Wegovy to be marketed on Hims & Hers telehealth platform. Him’s & Hers will cease selling knockoff Ozempic and Wegovy which was a questionable compunded medication. Hims will NOW sell Novo’s injectable Ozempic and Wegovy jabs, to U.S. persons with a script at the “same affordable self-pay prices as other telehealth platforms,” Novo declared.

March 5, 2026- FDA bashes Novo for not reporting severe adverse events

Novo Nordisk, is taking intense criticism from the FDA, Center for Drug Evaluation and Research (CDER), for not properly reporting alleged adverse events linked to its GLP-1 drugs, including a death. The FDA issued a warning letter dated March 5, relying on five incidences in which people prescribed the medications had an adverse event associated with the medication such as a stroke, suicidal ideations or even passed away by suicide – all of which Novo Nordisk allegedly refused to properly report to the FDA. The FDA alleged in its letter of warning to the corporation that Novo’s actions or inactions, “suggest systemic failures with your surveillance, receipt, evaluation, and reporting” of potential side effects.

March 1, 2026- Robert J. Stottlemire sues Novo alleging medication caused vision loss

A recent lawsuit alleges that Novo Nordisk’s medication lead to a patient suffering severe vision loss. The victim claims that the pharmaceutical entity did not warn of the risks of NAION caused by the GLP-1 medication. The victim, Robert J. Stottlemire, e-filed the Ozempic eye damage lawsuit against Novo Nordisk Inc. in Pennsylvania federal court. In pertinent part, Mr. Stottlemire alleges that Novo Nordisk violated certain state and federal consumer protection laws. As stated in the Ozempic class action lawsuit, the victim obtained an Ozempic prescription for treatment of Type 2 diabetes. He alleges that the Ozempic use caused him to develop non-arteritic anterior ischemic optic neuropathy (NAION), leading to substantial vision loss.

February 25,2026- Shrewsbury Massachusetts pharmaceutical company in hot water for fake Ozempic allegations

Novo Nordisk has filed an ozempic lawsuit against a local Shrewsbury Massachusetts pharmaceutical company alleging that the owner of the company wrongfully and incorrectly marketed a non authentic version of Wegovy and Ozempic. Novo asserts that the doctor misled her patients by asserting that the drugs she provided were approved by the FDA.

February 24, 2026- Ozempic and Wegovy announce prices cut up to 50% commencing in 2027

Novo Nordisk has announced that it intends to cut Ozempic and Wegovy list prices nearly 50% commencing in 2027. Novo Nordisk declared that it will slash U.S. list prices for Wegovy and Ozempic to $675 per month commencing Jan. 1, 2027. The pricing decision results from intensified competition from Eli Lilly’s Mounjaro and Zepbound products. The price cut will be nearly 50% for Wegovy and lowering the price of Ozempic  to 34 percent. The substantially slashed list prices will mostly help insured patients who have out-of-pocket costs that are directly tied to the medications sticker price. (i.e high deductibles or coinsurance) Novo has asserted that the alterations will have no affect on current discount programs utilized  by patients paying cash.

February 20, 2026- Ozempic could mitigate complications of osteoarthritis

Ozempic’s could potentially help repair cartilage to creaky joints. Semaglutide can mitigate complications of osteoarthritis and increase the thickness of cartilage between bones according to research in Cell Metabolism. The more cartilage equals enhanced cushion, which equates with minimized bone-on-bone grinding and lower pain.

February 12, 2026-

Researchers from the Veterans Health Administration health care system engaged in research utilizing information from March 2018 to March 2025. The analysts compared the vision of patients with Wegovy, Ozempic and Rybelsus prescriptions with patients with the diabetes medication known as sodium-glucose cotransporter-2 inhibitors (SGLT2i). SGLT2i include Jardiance, Farxiga and Invokana. The lead researcher, Dr. Kent Heberer, looked at data from 102,361 veterans and determined that the incidence rate of NAION was two times greater from patients with a semaglutide script as compared to people prescribed with SGLT2i drugs..

“In this nationwide cohort of US veterans with T2D, semaglutide initiators had a 2-fold NAION risk than SGLT2i initiators, while the absolute risk was low. Clinicians and patients should be counseled on the rare but evident increased risk of NAION after semaglutide initiation.”

– Dr. Kent Heberer, New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans with Type 2 Diabetes

February 10, 2026- Novo Nordisk sues Hims and Hers for compounded Ozempic knockoff

Novo Nordisk declared that it is pursuing an Ozempic lawsuit against telemedicine platform Hims & Hers for purportedly “deceiving patients and putting their health at risk” by marketing and distributing compounded knockoff versions of Ozempic and Wegovy drugs. Novo Nordisk asserts in its claims that Hims & Hers has encroached on Novo’s patent by distributing compounded fake Ozempic and Wegovy in the United States. As of this date, Hims & Hers is marketing the distribution of compounded GLP-1s. Last week, the Department of Health and Human Services Office of the General Counsel passed the matter on to the Justice Department for possible breaching the Federal Food, Drug, and Cosmetics Act. United States Code: Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301-392 (Suppl. 5 1934) Novo Nordisk Senior Vice President John F. Kuckelman made a firm statement:  “Throughout Novo Nordisk’s 103-year-long history, patient safety has always been our top priority. Hims & Hers is mass marketing unapproved knock-off versions of Wegovy® and Ozempic® that evade the FDA’s gold standard review process – that’s dangerous and deceptive to patients, and undermines the scientific innovation and regulatory rigor in place to ensure these treatments are safe and effective,” Novo Nordisk is demanding that the court make a declaratory judgment that Hims & Hers is infringing on Novo’s patent, forever banning Hims and Hers from distributing Semaglutide. Novo is also requesting monetary damages.  Hims & Hers fought back by stating: “Novo Nordisk’s lawsuit is a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care.”

(1) Calls to Washington State Poison Center tied to GLP-1 medications doubled since 2024. There were 421 GLP-1 phone calls in the calendar year of 2025. The number of these calls appear to be soaring every year. The calls typically are related to errors in medication or unintentional overdoses from injections. GLP-1 overdoses are awful and usually involve intense vomiting and severe nausea.

(2) Novo Nordisk announced that sales in 2026 will decline from 5% to 13 percent. This announcement caused Novo’s stock to fall 17 percent in one day. In the past year Novo’s stock has fallen 50%. Novo’s troubles can be traced back to: (a) an agreement with Trump to lower prices, (b) patent expiration in a number of countries including India, (c) compounded medication made by American companies. (d) Zepbound and Mounjaro manufactured by Elli Lilly lead to better weight loss results.

(3) Novo Nordisk threatened a lawsuit against Him & Hers after the company announced a cheaper knockoff of Wegovy. Him and Hers is offering a $49  monthly price to start with the price going up to $99. Novo issued a statement “The actions by Hims and Hers is illegal mass compounding that poses a signifricant risk to patient safety.”

February 6, 2026- Michelle Sword collapsed as a result of a diabetic coma

Michelle Sword, a 47 year old lady from the UK, collapsed as a result of a diabetic coma resulting from a fake ozempic jab. Ms. Sword purchased the counterfeit ozempic on Facebook using paypal. Within minutes of the injection, she collapsed and was unconscious. Her blood sugar fell to 0.2 millimoles per litre which can lead to death. Sadly, the pen was filled with insulin and not semaglutide.

February 5, 2026- Novo Nordisk files over 110 Ozempic lawsuits

Novo Nordisk has pursued over 110 lawsuits in U.S. federal courts spanning 32 states against companies allegedly illegally producing compounded “semaglutide.” These compounded medications most likely present severe risks to the health and safety of patients because these drugs may have high levels of impurities (up to 33%). These compounded medications may also be misbranded based on incorrectly labeled strengths. Numerous courts have issued temporary restraining orders (injunctions) or even permanent injuctions restraining the companies from selling the unlawful drugs.

February 4, 2026- Elli Lilly will be awarded regulatory approval, in 2nd quarter of 2026, for the pill version of its GLP-1 drugs.

Industry insiders and experts believe that Elli Lilly will be awarded regulatory approval, in the 2nd quarter of 2026, for the pill version of its blockbuster GLP-1 drugs. Lilly executive vehemently deny that the oral version of its pills will cannabalize sales of its GLP-1 injectible jabs. Lilly announced bullish projections of revenue for 2026 of up to 83 billion. The projections far exceed Wall Street’s estimates of 78 billion for 2026. Lilly had revenue of 65 billion in 2025, powered by the immense popularity of Lilly’s weight loss drugs Zepbound and Mounjaro. Lilly is crushing their prime competitor, Novo Nordisk. Lilly will also benefit from expanded coverage from Medicare.

February 3, 2026- Streamlined protocal for filing vison loss lawsuits in Federal MDL

The U.S. District Judge presiding over the GLP-1 lawsuits, relating to VISION LOSS, filed in federal courts has instituted a streamlined protocal for filing vison loss lawsuits against the GLP-1 manufacturers. Rather than filing new claims in assorted U.S. District Courts across the U.S., new lawsuits are eligible to be filed directly in the vision loss MDL (multidistrict litigation). This will avoid delays related to transferring lawsuits. This new process will permit the litigants to efficiently control the rapidly expanding ozempic litigation.

February 2nd, 2026-

Novo Nordisk’s stock fell precipitously after its sales and profit growth lowered in 2026. The stock fall was as a result of lower prices in the United States.  There are also exclusivity issues for Wegovy and Ozempic in Brazil, China, and Canada. The stock fell 14% in one day. The Danish drugmaker is struggling to regain its prominence amid tough competition.

January 29, 2026-

A recent study determined that diabetes medications such as Ozempic and Mounjaro might lead to a higher risk of chronic kidney disease and acute kidney injury than more established diabetes meds such as Invokana and Jardiance. The determinations were set forth in JAMA Internal Medicine, indicating that glucagon-like peptide-1 (GLP-1) receptor agonists lead to an 8.2% greater chance of chronic kidney disease than sodium-glucose cotransporter-2 (SGLT2) inhibitors.

January 28, 2026-

(1) Novo Nordisk issued a comprehensive press release that the U.S. Food and Drug Administration (FDA) has greenlighted Ozempic® to lower the chance of kidney disease getting worse, kidney failure (end-stage kidney disease), and death resulting from cardiovascular disease in people over 18 suffering through type two diabetes and chronic kidney disease (CKD). Anna Windle, PhD, Senior Vice President Clinical Development, Medical & Regulatory Affairs at Novo Nordisk opined that “Chronic kidney disease is very serious and common in patients living with type 2 diabetes and represents a critical need for adults living with these comorbidities. This approval for Ozempic® allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of adults and could have serious consequences if left untreated.”

January 27, 2026-

A federal court judge in Washington denied a motion to throw out Novo Nordisk’s ozempic lawsuit which alleged that a telehealth platform named Invigor engaged in false medical advertising concerning ozempic alternatives. The Justice determined that Novo has a “tangible stake”  in correcting allegedly misleading advertising which asserts that compounded medication is basically the same as Ozempic.

Jan 22, 2026-  Novo Nordisks’ There’s Only One Ozempic marketing campaign.

Justin Long and John Hodgman, two actors, have engaged in a reunion (of sorts) for Novo Nordisk’s ‘There’s Only One’ Ozempic campaign. Novo’s recent patient-focused advertising campaign seeks to draw a distinction between Ozempic and other garden variety GLP-1 drugs by emphasizing Ozempic’s numerous clinical benefits for people suffering through type 2 diabetes. The marketing campaign emphasizes Ozempic benefits of lowering A1C, providing more beneficial cardiovascular health and preventing kidney disease. Marketing enthusiasts might recall that the duo were involved in the iconic late 2000s Apple’s ‘Get a Mac’  long running marketing campaign. In the Apple campaign, John Long represented the Mac computer and the PC computer was repped by John Hodgman.

January 23, 2026-

January 16, 2026-

The Food and Drug Administration, this week, mandated that Eli Lilly and Novo Nordisk cease and desist warning labels concerning risks of suicidal thoughts and behavior from the labels of their increasingly popular weight-loss medications. The FDA’s action concludes over a year of studies related to side effects in patients with GLP-1 prescriptions. The FDA mandate pertains to Novo Nordisk’s Saxenda and Wegovy as well as Elli Lilly’s Zepbound. Researchers engaged in a very comprehensive review. The regulators determined that there was no increased risk of suicidal ideation or behavior actions linked to the use of the weight loss and diabetes medications. This decision does not  really effect any Ozempic lawsuit filed because the ozempic lawsuits were not alleging that glp-1s were linked to suicide.

January 15, 2026- California patient’s ozempic lawsuit

A California victim’s ozempic lawsuit versus Novo Nordisk alleges that he was diagnosed with vision loss after Ozempic jabs, leading to radical alterations to his life. The lawsuit (PDF) was pursued by Jason Lowe’s attorneys in the U.S. District Court for the Eastern District of Pennsylvania. Mr. Lowe asserts that Novo Nordisk refused to warn him or his medical providers about the real dangers of Ozempic jabs. Lowe claims, according to his GLP-1 lawsuit, that he recieved an Ozempic SCRIPT in the summer of 2023 as a result of a type 2 diabetes diagnosis. Sadly, in early 2024, Lowe commenced suffering through blurry vision as well as flashes in his right eye. Lowe became worried and visited an ophthalmologist. The opthalmologist announced a NAION diagnosis. Despite cancelling his Ozempic precription, he suffered through permanent loss of sight. The lawsuit cites the fact that Naion is untreatable and causes permanent loss of sight. Lowe’s lawsuit asserts that the manufacturer knew or should have known about the dangers of Ozempic. The lawsuit claims that there were reports of Optic Ischemic Neuropathy being caused by GLP-1 use as far back as 2012. Naion was believed to be linked to Wegovy and Ozempic by certain circles in as early as 2019, numerous years prior to Jason Lowe’s ozempic SCRIPT. Additionally, Lowe alleges that Novo Nordisk knew about NAION dangers when Ozempic clinical trials were ongoing. This is a a very serious allegation.

January 14, 2026- Ozempic generic coming to Canada in near future

January 13, 2026- Cornell study finds lower grocery bills by 5%

Weight-loss drugs like Zepbound and Mounjaro are altering the way people allocate funds on food. A massive study from Cornell University determined that households are lowering grocery bills by upwards of 5% in six months. The study results delineate an apparent and unmistakable pattern.  Fast-food restaurant spending has declined by a greater percentage. Snack foods and sugary foods such as candy had the steepest decline. Interestingly, several categories such as yogurt and fruit actually rose by a small amount. Spending on yogurts gained the highest, followed by fruit that is fresh, nutritional bars, and snacky meats. The Cornell study results are not surprising considering the fact that the GLP-1s are well know for their appetite-suppressing qualities. After six months of commencing an Ozempic type drug, households lowered grocery bills by approximately 5.3%.  Wealthy households lowered grocery spending by over 8%.  Households that continued the GLP-1 drugs, lowered grocery spending for nearly a year. As time passed, nonetheless, the amount of reduction slowly decreased.

January 13, 2026-

U.S. District Judge met with lawyers today, to resolve how to proceed with the Ozempic blindness MDL litigation in the future.

January 8, 2026-

When obese people cancel their weight-loss prescription they regain the weight faster than people who ceased an exercise program premised on diet and or exercise. Approximately half of patients with a GLP-1 script, cancel their medications within one year. The vast majority of these patients discontinue their prescription because of the high expense and adverse gastrointestinal side-effects. The researchers at BMJ declared that it is crucial to properly comprehend weight regain because of the risks of diabetes and heart disease from being overweight. Sam West, a postdoctoral researcher at the University of Oxford and partners looked at randomized trials and observational studies on greater than 6,000 patients over 18 who were fat and had a GLP-1 prescription compared. They compared this data with 3,000 people in weight loss programs that were behavioral in nature.

The comprehensive research study determined that people with weight-loss medication prescriptions regained on average of a bit less than a pound a month after terminating treatment. The research was titled, “Weight regain after cessation of medication for weight management: systematic review and meta-analysis.” Most people regained 10 pounds in a year. Researchers utilized modeling. They estimated that risk markers for heart disease and diabetes, elevated cholesterol and high blood pressure levels, would go back to to pre-treatment levels in less than 24 months. Sam West stated, “What we found particularly shocking was just how fast weight was regained after people stopped taking medication.” Patients who ceased weight-loss drugs regained weight nearly four times quicker than people who quit exercising or failed to maintain their diet.

December 24, 2025-

An ozempic law firm e-filed a GLP-1 lawsuit representing a victim, RAMONA WASHINGTON, from Philadelphia, Pennsylvania. The Plaintiff suffered from NAION as a result of taking Ozempic. See Washington v. Novo Nordisk Inc., et al., Docket No: 2:25-cv-07329. The lawsuit was designated by the victims’ lawyers as: “367 Torts – Personal Injury – Health Care/Pharmaceutical Personal Injury/Product Liability.”

December 22, 2025-

The Judicial Panel on Multidistrict Litigation (JPML) reported in December 2025 that there were 2,947 lawsuits pending in the national multidistrict litigation (MDL) pertaining to Ozempic and other GLP-1 medications.  This does not include the ozempic lawsuits and other GLP-1 litigation pending in the two New Jersey State Court MCLS. This also does not include over 20 NAION lawsuits pending in several federal courts nationwide that are in the process of being centralized in the New NAION MDL.

December 21, 2025-

Victims who irreversibly lost their eyesight have filed over 70 lawsuits seeking compensation and a settlement against Novo Nordisk and Eli Lilly. Currently, there are nearly 30 optic neuropathy lawsuits filed in federal court. There are greater than 40 similar NAION lawsuits in state courts. The cases pending in Federal court are presently being litigated in:  District of New Jersey,  Eastern District of Pennsylvania and Northern District of Texas. All 70 NAION “Ozempic lawsuits” allege that these GLP-1 medications caused victims a severe condition named non-arteritic anterior ischemic optic neuropathy.

December 17, 2025-

The U.S. Judicial Panel on Multidistrict Litigation, which manages mass tort litigation in federal court, ruled in favor of victims and their ozempic law firms. The panel determined that the GLP-1 claims related to vision loss will be litigated in a separate federal court multi-district litigation (MDL) than the GLP-1 digestive complications MDL. THE JPML ruled that: “On the basis of the papers filed and the hearing session held, we find that the actions listed on Schedule A involve common questions of fact and that centralization in the Eastern District of Pennsylvania will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation.”

Both the Ozempic vision loss MDL and the Ozempic stomach side effects MDL will be pending in Pennsylvania federal court before a single federal court justice, Judge Marston. The  judicial panel reasoned that the alleged injuries were different different from the gastrointestinal damages related to MDL No. 3094. The panel determined that there would be major overlap between pretrial proceedings in these litigations. In addition, certain plaintiffs allege that they suffer from both the gastrointestinal damages alleged in MDL No. 3094 and the NAION MDL. The panel also reasoned that the NAION lawsuits pertain to the same defendants and the same victims’ lawyers.  The panel also figurately threw a figurative bouquet at Judge Marston, stating “Marston thus is uniquely well-positioned to advance this litigation efficiently.”

December 16, 2025- Judge Marston sets 2026 scheduling mandates and deadlines for Ozempic lawsuit

Judge Marston promulgated case management order #29 (PDF) determining crucial deadlines for resolving pertinent litigation management issues throughout the calendar year of 2026. The case management order mandates that victims and their ozempic law firms serve expert reports by on or before January 2, 2026. The manufacturers lawyers were provided a compliance deadline by on or before February 12th, 2026. Plaintiffs must rebut the manufacturer’s expert testimony reports by on or before February 23, 2026. Justice Marston required that all attorneys complete expert depositions by on or before April 10th, 2026.

Justice Marston’s pretrial scheduling rules set a deadline for motions to exclude expert testimony by on or before April 28, 2026. Summary judgment motions must be filed by April 30th. Legal briefs related to summary judgment motions must be e-filed by on or before June 16, 2026. Objections to summary judgment motions needs be e-filed prior to July 24th, 2026.

December 3, 2025-

Many states have decided to refuse coverage for the GLP-1 weight-loss drugs for obese patients who don’t have type 2 diabetes, evading a likelihood to lower cancer rates, diabetes and heart disease. There are several states that have opted to provide coverage for the medication. Almost 40 percent of people in the state-federal program which covers low-income people are obese. States that provide coverage for GLP-1 drugs are blowing holes in their budget.

January 31, 2025-

Diane Dyess filed a 222 page Ozempic lawsuit ( DYESS v. NOVO NORDISK INC. et al) alleging severe side effects in the MDL in Pennsylvania federal court. The lawsuit is now a component of an existing multidistrict litigation which alleges that Novo Nordisk’s glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to severe injuries such as gastroparesis. The GLP-1 lawsuit asserts that Novo Nordisk did not provide sufficient warnings concerning the risk of stomach paralysis and other severe complications which are alleged to be caused by Ozempic. Ms. Dyess alleged that Novo Nordisk was part of a confusing, deceptive and misleading marketing scheme attempting promotion of the type 2 diabetes medication. The lawsuit asserts, “Defendants intentionally omitted other facts that they knew to be true from their labels, physician communications, marketing, website, public statements and other public facing communications,”  The Ozempic side effects class action argues Novo Nordisk’s marketing of Ozempic downplayed the risks of adverse events and failed to adequately warn health care providers and patients about the potential for serious complications. Dianne

Dyess alleged that Novo Nordisk’s marketing scheme was so pervasive it resulted in widespread off-label prescriptions for the medication. The ozempic lawsuit states, “Defendants’ aggressive marketing of Ozempic and other GLP-1 RAs created a perception that these drugs were a magic solution for weight loss, leading to increased demand and off-label use.” Dyess’ complaint alleges the following causes of action: negligence, failure to warn, strict liability, breach of express warranty, breach of implied warranty, fraudulent concealment, intentional misrepresentation, negligent misrepresentation, strict product liability misrepresentation, innocent misrepresentation, negligent design and strict liability design defect. Ms. Dyess demanded a trial by jury, compensatory damages, punitive damages as well as declaratory and injunctive relief.

November 30, 2025-

Scott Angarola, a 47-year-old victim residing in Pennsylvania claims blindness subsequent to Ozempic usage. He alleges that the vison loss was caused by the Ozempic medication. Pursuant to the Ozempic lawsuit pursued against Novo Nordisk, Angarola commenced Ozempic usage in 2022. He was under a physician’s supervision to treat higher blood sugar caused by type 2 diabetes. After several months, Mr. Angarola started noticing vision issues and received a devastating diagnosis of non-arteritic anterior ischemic optic neuropathy (NAION).  Angarola asserts that Novo Nordisk failed to warn about the risks of blindness. He cited previous very concerning adverse-event reports pertaining to Ozempic medication and safety reports that were internal at Novo Nordisk. He also references concerning studies associating semaglutide usage with up to twice the chance of optic-nerve ischemia as compared to different treatment for diabetes.

November 23, 2025-

There was significant research set forth in the Annals of Internal Medicine. Researchers from Brigham and Women’s Hospital and Harvard Medical School determined that GLP-1 receptor agonists all have a similar levels of gastrointestinal problems. While all the GLP-1 medications are different, the research found that gastrointestinal side effect are more prevalent than the side effects in other types of type two diabetes drugs.

Dr. Elizabetta Patorno was the lead researcher in a comprehensive study involving a huge cohort of greater than 200,000 medical records.  The study focused on gastrointestinal side effects of semaglutide, tirzepatide and dulaglutide (Trulicity) when utilized for treatment of type 2 diabetes. The researchers compared data with complications reported by people prescribed with sodium-glucose cotransporter 2 (SGLT-2) inhibitors such as Januvia and Farxiga. The research indicates that three GLP-1 medications had a very comparable chance of gastroparesis, pancreatitis and bowel obstruction diagnosis that mandated emergency room visits or hospitalizations. Nonetheless, people prescribed with this medication are looking at greater risks of gastrointestinal side effects when compared to SGLT-2 prescriptions.

The research shows that Ozempic patients faced an over 21% greater chance of GI problems. People with Trulicity scripts were facing an over 35% greater risk. The medical analysts determined that that the greatest chance of GI complications was associated with Mounjaro medication.  Mounjaro users were facing greater than 49% greater risk of stomach paralysis and associated GI side effects as compared to SGLT-2 medications. “These findings suggest that dulaglutide, semaglutide, and tirzepatide have similar gastrointestinal safety profiles in adults with T2D. This study provides clinicians with evidence to weigh the benefits and risks of these medications.” Dr. Elizabetta Patorno, Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes

November 23, 2025- Medical malpractice lawsuit related to GLP-1 scripts

The New Jersey Supreme Court has determined that lawsuits filed in NEW JERSEY STATE COURTS related to Ozempic (Wegovy) vision loss, NAION and vision complications will continue to be dealt with separately from the ongoing Ozempic lawsuits related to stomach paralysis and assorted gastrointestinal complications. The NAION lawsuits will be part of a different MCL in Bergen County NJ presided by Superior Court Judge Gregg A. Padovano. Justice Padovano will also preside over the stomach paralysis lawsuits in NJ State Courts. Read the notice to the NJ bar PDF.  In June of 2024, twenty one GLP-1 victims suffering through NAION, with pending Ozempic lawsuits (or Wegovy lawsuits) in New Jersey State Courts requested that the Administrative Office of the Courts establish a multicounty litigation (MCL). Both NAION and gastrointestinal side effects Ozempic lawsuits will be heard by a single Justice in “coordinated” pretrial proceedings in separate MCLs. An MCL in NJ is similar to a federal MDL in that it is a consolidated mass tort proceeding seeking to streamline the discovery process. The intent is to prevent judges from issuing inconsistent decisions / orders. This allows a huge number of similarly situated lawsuits to proceed forward in an orderly and consistent manner. The reason that ozempic lawsuits can be filed in New Jersey State Court and stay in New Jersey state court is based on [Ozempic manufacturer] Novo Nordisk being a company based, at least in part, in New Jersey (NJ).”

November 17, 2025- GLP-1 medication to be sold cheaper to cash customers

Novo Nordisk announced that it is lowering the direct-to-consumer prices of Wegovy and Ozempic to $349 per month. The price was originally $499 per month for cash customers. Novo Nordisk also announced a new temporary offer which is introductory in nature. This offer permits new cash patients to get the two lowest amount of doses of the medication for only $199 per month for the initial two months of Ozempic medication treatment. Novo Nordisk announced this news right after American President Donald J. Trump reached a deal with Novo Nordisk and Eli Lilly, the makers of Mounjaro and Zepbound to sell their revolutionary GLP-1 medications at a more affordable price and make the GLP-1 drugs more accessible to the public.

November 11, 2025-

A Cullman Alabama medical clinic is steering down the barrel of an ozempic lawsuit pursued by the state of Alabama. The Attorney General of Alabama, Steve Marshall, alleges that “Aurora IV and Wellness” gave customers unsafe and unapproved for human use weight-loss medication. This is not your garden variety Ozempic lawsuit. The Alabama AG alleges that patients at the health clinic thought they were receiving normal GLP-1 prescriptions such as Ozempic medication. However, these victims were injected with research-grade medications that are not allowed for human to use. A court issued a temporary restraining order (TRO) preventing the health clinic from doing business while the court analyzed the serious allegations and disturbing claims.

November 5, 2025-

An Iowa corporation was alleged to be selling counterfeit Ozempic. The accused company settled the dispute by paying $132,249 to a Michigan corporation. The financial resolution was reached subsequent to the Iowa Board of Pharmacy fining SmartScripts $25,000 in August 2025. The CEO’s license was put on probation for five years based on allegation of selling the fake Ozempic. Thankfully, the board of pharmacy in Iowa mandated that SmartScripts, located near Iowa City, to be monitored and provide periodic detailed reports.

October 27, 2025-

A couple of recent studies were presented at the yearly convention of the American Academy of Ophthalmology. Two recent Ozempic studies were set forth in October of 2025 at the 129^th annual meeting of the American Academy of Ophthalmology.  The first study determined that GLP-1 drugs may lead to a higher risk of diabetic retinopathy and non-arteritic anterior ischemic optic neuropathy (NAION). A 2nd study seems to indicate that Ozempic may provide protection from dry age-related macular degeneration (AMD). These studies presented differing results: one study determined that GLP-1 medications may increase the chance of of diabetic retinopathy and non-arteritic anterior ischemic optic neuropathy (NAION). A different research study tends to show that the medication could provide protection from dry age-related macular degeneration (AMD). Researchers impressively collaborated internationally to make this groundbreaking study a reality.  The researchers were from:

• University of Ottawa Eye Institute,
• University of Toronto,
• McMaster University,
• Doheny Eye Institute UCLA

Study #1 presented at the American Academy of Ophthalmology This research study was the biggest global study on this topic. The study utilized data culled from the World Health Organization’s international database comprised of drug safety reports. The researchers reviewed data on over 117,000 patients with diabetes diagnosis who were prescribed semaglutide (GLP-1), empagliflozin, exenatide, tirzepatide, or insulin. Results established that patients utilizing GLP-1 drugs had a 68.6 greater likelihood to suffer though a NAION diagnosis and at least eight times more likely to be diagnosed with diabetic retinopathy than patients prescribed empagliflozin, exenatide, insulin or metformin. The research determined no important association between tirzepatide use (the main component of other GLP-1 drugs such as  Mounjaro and Zepbound) and NAION or diabetic retinopathy.

A press release issued by the American Academy of Ophthalmology stated that a recent study has “found GLP-1 drugs can increase the risk of diabetic retinopathy and non-arteritic anterior ischemic optic neuropathy (NAION).”  The press release specifically states: “Results showed that people using GLP-1 drugs were 68.6 times more likely to develop NAION and eight times more likely to develop diabetic retinopathy than those taking empagliflozin, exenatide, insulin or metformin. The analysis found no significant association between tirzepatide (the active ingredient in other GLP-1 medications including Mounjaro and Zepbound) and NAION or diabetic retinopathy.”

Study #2 presented at the American Academy of Ophthalmology meeting In a different research project, analyst at Cleveland Clinic Cole Eye Institute looked at how GLP-1 medications affect the risk of being diagnosed with AMD. Researchers  evaluated data from greater than 430,000 people 50 or older who were prescribed either a GLP-1, sodium-glucose cotransporter 2 inhibitors (SGLT2i), metformin or insulin to treat diabetes for two years or more at a one ophthalmic center. The 7,319 people prescribed a GLP-1 for 5 years indicated a much lower risk of a dry AMD  diagnosis. This was 63 percent lower than people takings metformin and 58 percent lower chance than people taking insulin. There was a 54 percent lower risk than those prescribed a SGLT2i. The protective effect was greater among people looked at for up to a 5 years period. The research indicated no real protection from the wet type of AMD.

October 20, 2025-

Plaintiffs’ and Defendant Novo Nordisk’s issued a joint request to extend the case management deadlines in the federal MDL. The Court issued CASE MANAGEMENT ORDER NO. 28 as a result of that joint request and extended certain deadlines. The case management order allows victims until December 19th, 2025 to provide expert reports. The manufacturers are allowed until January 30th to provide expert reports. Victims are allowed until February 9th, 2026 to provide rebuttal expert reports.  The deadline for all parties to finish expert depositions is March 27, 2026. The deadline for all parties to file motions to exclude expert testimony is April 14, 2026. Summary judgment motions must be e-filed by on or before April 16.

It seems like Judge Marston will wait until after the above mentioned discovery deadlines are completed and then Judge Marston will in all likelihood order that the litigants pick several representative Ozempic lawsuits for initial bellwether trials. (A bellwether trial in a federal court multidistrict litigation (MDL) is a test case that is litigated in federal court to aid in gauging the strength and potential monetary value of a large grouping of similar situated filed lawsuits. The results of these bellwether trials are influential in providing a “litmus test” to guide possible settlement negotiations and help manage the resolution of the litigation process more smoothly.)

October 13, 2025-

Ozempic is now one of the largest drug lawsuits in history. There are approximately 3,000 Ozempic lawsuits filed in U.S. courts and possible damages could be well over $2 billion.

October 10, 2025-

A recent study determined that complications of Ozempic and Wegovy may be linked to a greater chance of kidney damage. According to the study- Mounjaro and Zepbound, are not linked to Kidney Injuries The study, Preprints.org (PDF) determined that there was a “disproportionate” amount of acute kidney injuries (AKIs) caused by GLP-1 medication. The study reviewed Adverse Event Reporting System (FAERS) reports submitted to U.S. Food and Drug Administration’s (FDA). The study is  questionable because it is not peer-reviewed and has not been published.  Relying on adverse event reporting is unreliable on its face.

October 08, 2025- Florida Resident files Ozempic Lawsuit

Numerous lawsuits have been filed in New Jersey state courts for victims who used Ozempic or Wegovy and were diagnosed with NAION. The State Court route is a separate and distinct avenue for victims who do not want to file an Ozempic lawsuit in Federal Court. On October 8, 2025, an Ozempic lawsuit was filed on behalf of a resident of Florida. The  Florida victim was diagnosed with NAION in both eyes allegedly caused by Ozempic medication. See Malacos  v. Novo Nordisk Inc., Docket No: MID-L-007163-25.

October 7, 2025

Victim’s lawyers are demanding that the U.S. Judicial Panel on Multidistrict Litigation (JPML) establish a different and separate MDL in Federal Court for lawsuits alleging vision loss from GLP-1 drugs. The victims do not want to consolidate the vision loss claims into the existing MDL which is handling lawsuits pertaining to stomach paralysis and  gastrointestinal damages. (The existing MDL is in the Eastern District of Pennsylvania under U.S. District Judge Karen S. Marston.) In August of 2025, Eli Lilly, the manufacturer of Mounjaro and Zepbound, filed paperwork with the U.S. Judicial Panel on Multidistrict Litigation (JPML), requesting that  GLP-1 vision loss claims should also be handled by Judge Marston in the existing MDL. The Victims’ Ozempic lawyers filed a memorandum in opposition (PDF) requesting that the litigation be litigated before a different judge in New Jersey Federal Court. “At bottom, Lilly argues that dozens of filed Plaintiffs suffering from vision loss (and hundreds or thousands of Plaintiffs whose claims are not yet filed) should be denied the opportunity to advance their claims and instead get in line behind thousands of Plaintiffs pursuing gastrointestinal claims that involve fundamentally different core allegations and evidence.” – Memorandum in Opposition to Eli Lilly and Company’s Motion for Transfer of Actions Elli Lilly filed a response (PDF).. Novo Nordisk also wrote a memo (PDF) siding with Elli Lilly.

October 3, 2025-

As of October 3, 2025, there are over 2,809 lawsuits in the MDL pertaining to Ozempic, Mounjaro and numerous other GLP-1 medications. In September 2025, there were over130 new victims filing claims in the MDL. The MDL for the GLP-1 has been expanding quickly in the last several months. A decent percentage of the claims filed are Ozempic lawsuits.

October 2, 2025-

A North Carolina victim suffering through stomach paralysis, after being prescribed Ozempic, asserts that his complications endured for months after he stopped taking Ozempic medication. The lawsuit (PDF) against Novo Nordisk is being pursued by Michael Hemenway in the U.S. District Court for the Eastern District of Pennsylvania. The Ozempic lawsuit, alleges that Hemenway was prescribed Ozempic by his medical providers to help treat type 2 diabetes in October 2023. Hemenway took ozempic until January 2024. In January 2024, Hemenway started suffering through nausea, epigastric pain, vomiting as well as acute abdominal pain. Mr. Hemenway suffered through a distended stomach which contained food and liquids. Hemenway, eventually received a devastating diagnosis of gastroparesis. Mr. Hemenway claimed in his lawsuit that “Based on Plaintiff’s symptoms, Plaintiff was instructed to stop taking Ozempic, but despite stopping the medication, Plaintiff continued to suffer from the same symptoms.” – Michael Hemenway v. Novo Nordisk Inc. In February 2024, Mr. Hemenway had a a gastric emptying study confirming that Mr. Hemenway still was diagnosed with stomach paralysis.  According to the Ozempic lawsuit, despite a gastroparesis diet suggested by his doctors, he continued to suffer through recurring side effects.

September 26, 2025-

A Delaware victim, Paula Wachter, alleges in a Mounjaro lawsuit that she spent two weeks in the hospital as a result of Mounjaro complications. She suffered through bowel obstruction leading to severe abdominal pain and cyclic vomiting. Ms. Wachter was prescribed the Eli Lilly medication which caused the need for emergency surgery. Ms. Wachter endured physical rehabilitation as well as permanent injuries.

September 24, 2025-

A Wisconsin victims’ Ozempic law suit asserts that the manufacturers of Ozempic, the Danish Corporation Novo Nordisk, did not properly alert victims and physicians about the dangers of bowel obstruction, stomach paralysis, and other severe gastrointestinal side effects caused by Ozempic. The lawsuit (PDF) victim is Rose Orta who filed a claim in the U.S. District Court for the Eastern District of Pennsylvania against Novo Nordisk Inc., the  Danish maker of Ozempic.

September 17, 2025-

Attorneys in the federal Ozempic lawsuit MDL agreed to a Case Management Order that implemented a Master Complaint as well as a Short Form Complaint. This strategy streamlines the MDL process and is a good step forward for victims. The short form complaint allows claimants to pursue their claims more easily. Plaintiff’s are not required to restate all allegations in their short form complaint. There is one important downside for Ozempic lawyers that we are required to refile existing lawsuits using the short form complaint. Defendants will be permitted 60 days to answer the Master Complaint.

September 17, 2025-

A new Ozempic lawsuit was filed in New Jersey State Court. The victim is a Baltimore, Maryland resident who suffers from non-arteritic anterior ischemic optic neuropathy (NAION). The victim asserts that the Ozempic injections lead to her NAION diagnosis. The case is Christensen v. Novo Nordisk Inc., Docket No. MID-L-0056489-25, and was filed on September 8, 2025.

September 12, 2025-

Novo Nordisk, the manufacturer of the diabetes and weight loss drugs Wegovy and Ozempic, is in the process of laying off 9,000 workers as a result of increased competition in the obesity drug market place. Novo Nordisk has been competing with US competitor, Eli Lilly. The layoffs announced by Novo Nordisk Wednesday is greater than 11% of  Novo Nordisk’s total employees.

September 11, 2025-

Eli Lilly is pursuing a motion to centralize federal lawsuits that allege vision loss from Ozempic and related drugs. More specifically Eli Lilly is attempting to centralize Ozempic lawsuits pertaining to non-arteritic anterior ischemic optic neuropathy (NAION). The pleading requests that the Federal Court creates a new MDL or in  the alternative consolidate NAION lawsuits into MDL No. 3094 which is already underway. The existing MDL in federal Court pertains to gastrointestinal injuries involving GLP-1 drugs.  Lilly has requested that the Ozempic lawsuits for eye injuries  also be delegated to Justice Karen Marston in the Eastern District of Pennsylvania. Judge Marston is currently presiding over MDL 3094. Eli Lilly asserts that Judge Marston is familiar with the pertinent science, history of regulation and the inner workings of the case structure of the Ozempic lawsuits. (Please note that there many vision loss lawsuits filed in New Jersey state court which may turn into a coordinated mass tort lawsuit.)

September 9, 2025-

The FDA issued a warning letter against Novo Nordisk concerning a promotional communications, direct-to-consumer video titled “An Oprah Special: Shame, Blame, and the Weight Loss Revolution,” regarding WEGOVY and OZEMPIC®.

September 6, 2025-

A Virginia resident claims that she endured serious eye damage as a result of  complications from Ozempic and Trulicity. The victim asserts that the prescriptions caused her intestines to shut down, causing severe blockages. The lawsuit (PDF) was e- filed in the U.S. District Court for the Eastern District of Pennsylvania. The Ozempic lawsuit names Novo Nordisk, the manufacturers of Ozempic, as well as Eli Lilly, the manufacturers of Trulicity, as the responsible entities.

September 5, 2025-

A class-action Zepbound lawsuit was filed against CVS Caremark premised on a CVS’ policy to terminate Zepbound coverage. A CVS benefit manager informed customers concerning CVS’ policy changes. CVS insisted that there was “another covered medication that’s safe and effective for your condition and may cost less.” CVS was referencing Wegovy, manufactured by Novo Nordisk. CVS Caremark announced a lucrative partnership with Novo Nordisk right before the announcement to cease Zepbound coverage.  Zepbound is manufactured by Novo Nordisk’s chief competitor, Elli Lilly. CVS customers and medical providers pushed back- stating that the GLP-1 medications aren’t interchangeable medically. It has been reported that CVS was denying coverage for Zepbound despite appeals and complaints by both patients and their physicians.

September 1, 2025-

Eli Lilly is requesting that a federal a panel of judges establish another multidistrict litigation (MDL) to account for the expanding amount of NAION vision loss lawsuits that are being pursued by victims who were prescribed Mounjaro, Ozempic and other GLP-1 prescriptions. Eli Lilly argues that a new potential MDL be overseen and managed by to the same judge of the U.S. District Court handling several thousand stomach paralysis claims involving the exact same GLP-1 Medications.

August 25, 2025-

A Maryland victim who was prescribed Ozempic, causing him to be legally blind, filed an Ozempic lawsuit. The man asserted that Novo Nordisk had a legal obligation to warn victims that vision loss was a potential complication of Ozempic usage. Todd Engel, 62 took Ozempic in the 2023 time period for treatment of Type 2 diabetes. The lawsuit alleged that four months later, Engel  suffered through nonarteritic anterior ischemic optic neuropathy, or NAION. An Ozempic lawsuit was pursued in state court in NJ by a Long Island, New York victim who received a devastating diagnoses of NAION. See Barzyz v. Novo Nordisk Inc., Docket No: MID-L-005991-25.

August 15, 2025-

Novo Nordisk expanded their legal maneuverings related to ozempic in an attempt to protect the United States public from “unsafe, non-FDA-approved compounded semaglutide.” According to Novo Nordisk’s press release issued in August 2025: “New legal actions are directed at organizations involved in illegal activities, including violating laws prohibiting the corporate practice of medicine, interfering with doctors’ decisions and steering patients toward unapproved knockoff drugs under the false guise of personalization • Novo Nordisk has filed more than 130 lawsuits across 40 states, resulting in 44 permanent injunctions to stop unsafe, illegal marketing and selling of knockoff Wegovy® and Ozempic®.”

August 17, 2025-

August 14, 2025-

An Ozempic lawsuit was filed on behalf of a middle aged Miami, Florida resident who was diagnosed with NAION caused by Ozempic.  The lawsuit is Delgado v. Novo Nordisk Inc., Docket No: MID-L-0047-25. Numerous Ozempic vision loss lawsuits are now being filed by lawyers in New Jersey state courts for victims prescribed Ozempic or Wegovy. Many of these victims were diagnosed with NAION. Ozempic lawsuit settlement amounts for these vision loss cases are unknown at this time.

August 13, 2025-

Justice KAREN SPENCER MARSTON, Federal Court Judge IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA issued a scheduling order for the multidistrict litigation (MDL). “AND NOW, this 13th day of August, 2025, it is ORDERED that the parties shall appear in Courtroom 16B for a STATUS CONFERENCE before the Honorable Karen Spencer Marston on the following days: • September 30, 2025, at 1:00 p.m. • November 18, 2025, at 1:00 p.m. • December 16, 2025, at 1:00 p.m. • January 13, 2026, at 1:00 p.m. • February 10, 2026 at 1:00 p.m. • March 9, 2026 at 1:00 p.m. • April 14, 2026 at 1:00 p.m. .

August 7, 2025-

Novo Nordisk released its revised 2025 outlook. Novo Nordisk trimmed its guidance for 2025 as a result of lower than expected sales expectations for the remainder of 2025. These lower sales expectations for the remainder of 2025 reflect expanding usage of compounded GLP-1s, increased competition and lessening market expansion.

August 4, 2025-

On August 4, 2025, Novo Nordisk e-filed lawsuits against 14 corporations. These businesses that were sued are pharmacies alleged to be involved in compounding and  or distributing of semaglutide drugs. The lawsuits are premised on claims that these pharmacies were involved in producing or distributing semaglutide drugs that are not FDA-approved. These medications are often sourced from shady chains of supply. Some of these medications contain questionble and perhaps shady foreign active pharmaceutical mixes.

July 31, 2025- Patients suffer from debilitating medical side effects

(1) An Ohio resident filed a Mounjaro lawsuit. The victim asserts that after less than 12 months of injections, she suffers from stomach paralysis as well as other complications The lawsuit (PDF) is being pursued by Cynthia L. Pryor and her Ozempic lawyers in the U.S. District Court for the Eastern District of Pennsylvania.  Pryor asserts that Eli Lilly did not properly warn about the dangers of Mounjaro. She asserts that she endured gastrointestinal side effects.

(2) Terry Smith of Indiana filed a GLP-1 lawsuit on July 31, 2025 against Eli Lilly and Novo Nordisk. In pertinent part,  Mr. Smith alleged that “Defendants have downplayed the nature, duration, extent, and seriousness of gastrointestinal events and failed to warn about other adverse events caused by their GLP-1Ras,” Smith alleges that Ozempic, Trulicity, and Victoza caused him to suffer through gastroparesis among other conditions.  He claims that the medications lead to debilitating vomiting and severe abdominal pain. His complaint alleges that he had no choice but to seek emergency medical treatment as a result of his side effects. The lawsuit alleges that rather than alerting patients about muscle loss, “Lilly has instead invested in developing combination drugs to combat the muscle loss.”

July 30, 2025 – NAION CONSOLIDATED proceeding in New Jersey?

The Judge has approved the manufacturers demand for quick discovery as well as motions related to pivotal issues:

• • 1. Whether diagnostic testing for gastroparesis is reliable,
    2.  Are the written warnings (labels) sufficiently adequate?

August 23, 2024- Ozempic leads to suicidal thoughts?

In a recent study in a respected journal of medicine, JAMA Network Open, researchers working for the the University of Zurich and the Zucker School of Medicine determined that ozempic users disproportionately suffer from suicidal ideations while prescribed Ozempic. The finding state,” his disproportionality analysis through the case-control design based on the World Health Organization global database collecting suspected adverse drug reactions, identified a disproportionality signal of suicidal ideation with semaglutide, which remained significant when comparing semaglutide with dapagliflozin and metformin and in the subgroup of patients with co-reported use of antidepressants and benzodiazepines.”

August 8, 2024 – Status Conference in MDL Ozempic class action

On August 8, 2024. There was a status conference between the leadership of the MDL and the presiding Justice. Case management order #17 was the end result of the conference. Case management order #17 was titled “ESTABLISHING TIME AND EXPENSE PROTOCOL AND COMMON BENEFIT FUNDS.” The order states in pertinent part “This Order is entered to provide for the fair and equitable sharing among plaintiffs and their counsel of the burden of services performed and expenses incurred by attorneys acting for the common benefit of all plaintiffs in this complex litigation.”

August 6, 2024 –  MDL Class Action Lawsuit

In July and August of 2024, the number of Ozempic lawsuits in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation – which is commonly known as the Ozempic class action (among lay people) had a major increase in filed GLP-1 claims. As of July 2024, the litigation (MDL 3094) had a bit over 110 lawsuits.  In August of 2024, the number of Ozempic, Wegovy and other GLP-1  lawsuits increased to approximately 345. That constitutes more than 200% increase in around 30 days!

August 2024

The European Medicines Agency mandated updated warning labels for Ozempic and other drugs to warn of the risk of vision loss as well as NAION risks

July 6, 2024:  Ozempic MDL growing slowly-

Only four additional lawsuits were filed into the MDL in June of 2024. As of the end of June 2024, there are only 105 lawsuits in this MDL. The Ozempic MDL also includes Wegovy, Mounjaro, Rybelsus and Zepbound.

July 31st, 2024-  Honorable Lawrence F. Stengel (Retired) appointed as Special Discovery Master to oversee discovery

“Pursuant to Federal Rule of Civil Procedure 53(a)(1)(C), the Court hereby appoints the Honorable Lawrence F. Stengel (Retired) as Special Discovery Master to oversee discovery between and among the parties and third parties. The Court has considered the Affidavit of Lawrence F. Stengel, supplied pursuant to Federal Rule of Civil Procedure 53(b)(3), a copy of which is attached to this Order, and is confident that he possesses the requisite skills, experience, and other attributes necessary to serve in the capacity as Special Discovery Master in this MDL.”  CASE MANAGEMENT ORDER NO. 16- SPECIAL MASTER APPOINTMENT AND PROTOCOL

July 5, 2024- Ozempic linked to rare vision loss

Recent preliminary research indicates a connection between semaglutide to a rare eye problem, nonarteritic anterior ischemic optic neuropathy. This eye condition can lead to blindness. This study was recently published in JAMA Ophthalmology. The study sets forth a possible link from diabetes to semaglutide to nonarteritic anterior ischemic optic neuropathy. The study determined that victims with type 2 diabetes who took semaglutide had a four times greater chance to get diagnosed with NAION (nonarteritic anterior ischemic optic neuropathy) as compared to patients with a diabetes diagnosis prescribed different medications. Overweight people who were prescribed semaglutide for weight management had a greater than seven times risk of NAION.

July, 2024-

Harvard researchers published a study that indicated a seven times greater likelihood of NAION among Ozempic users.

2024-  Zepbound cures sleep apnea?

Elli Lilly announced findings from two studies that tracked obese patients who suffer from moderate to severe obstructive sleep apnea. Study participants were prescribed with Tirzepatide (a.k.a Zepbound) for one year via injection. (70 percent of study participants were male and 30 percent female) One of the studies evaluated patients who were utilizing a sleep apnea machine known as positive airway pressure device. The 2nd study evaluated patients who did not utilize the medical device. All patients in both studies were prescribed tirzepatide. Patients in the  studies who imbibed tirzepatide had major reductions in sleep events. Those patients also lost weight, approximately 20% of their body weight.  Eli Lilly’s drug is tirzepatide, but is marketed to the public in the United States as Zepbound. The studies indicate that Zepbound lowers in obese people, the severity of obstructive sleep apnea (OSA). In Lilly’s clinical trials for Zepbound, patients were observed with lowered irregular breathing events by over 50 percent in one research paper and nearly 62% in  a different study. Zepbound, also lowered disordered sleep breathing, disturbances while sleeping as well as sleep-related impairment.

June 10, 2024:  New Ozempic judge in MDL-

U.S. District Judge Karen Marston will now be the judge in charge of the Ozempic class action MDL lawsuits. (This includes other similar drugs) Marston was previously a tough federal prosecutor whose career as a justice commenced in 2019. The Judicial Panel on Multidistrict Litigation choose her to preside over the complex Ozempic litigation.  Many lawyers estimate that there will be over 10,000 lawsuits filed into the MDL. Sadly, U.S. District Judge, Gene E.K. Pratter, died unexpectant in May 2024 as a result of chronic obstructive pulmonary disease. Attorneys have been preparing cases. The lawyers have been working on a Plaintiff’s fact sheet.